Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the

Dow Jones Industrial Average

(

^DJI

) trading up 65 points (0.4%) at 17,452 as of Wednesday, Jan. 28, 2015, 12:05 PM ET. The NYSE advances/declines ratio sits at 1,122 issues advancing vs. 1,846 declining with 156 unchanged.

The Drugs industry currently sits down 1.0% versus the S&P 500, which is up 0.1%. On the negative front, top decliners within the industry include

Alnylam Pharmaceuticals

(

ALNY

), down 3.4%,

Celgene

(

CELG

), down 1.2%,

Gilead

(

GILD

), down 1.1%,

Amgen

(

AMGN

), down 1.3% and

Actavis

(

ACT

), down 0.4%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3.

Endo International

(

ENDP

) is one of the companies pushing the Drugs industry higher today. As of noon trading, Endo International is up $2.31 (2.9%) to $82.04 on heavy volume. Thus far, 2.0 million shares of Endo International exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $79.60-$82.88 after having opened the day at $79.96 as compared to the previous trading day's close of $79.73.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Endo International plc, a specialty healthcare company, develops, manufactures, markets, and distributes branded pharmaceutical and generic products, and medical devices worldwide. Endo International has a market cap of $12.2 billion and is part of the health care sector. Shares are up 10.6% year-to-date as of the close of trading on Tuesday. Currently there are 10 analysts who rate Endo International a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates

Endo International

as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity. Get the full

Endo International Ratings Report

TheStreet Recommends

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading,

Valeant Pharmaceuticals International

(

VRX

) is up $1.04 (0.7%) to $161.84 on average volume. Thus far, 1.0 million shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 2.2 million shares. The stock has ranged in price between $160.82-$162.80 after having opened the day at $161.28 as compared to the previous trading day's close of $160.80.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter (OTC) products, and medical devices in the areas of eye health, dermatology, and neurology therapeutic classes worldwide. Valeant Pharmaceuticals International has a market cap of $53.7 billion and is part of the health care sector. Shares are up 12.4% year-to-date as of the close of trading on Tuesday. Currently there are 9 analysts who rate Valeant Pharmaceuticals International a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates

Valeant Pharmaceuticals International

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, compelling growth in net income, good cash flow from operations, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full

Valeant Pharmaceuticals International Ratings Report

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading,

Johnson & Johnson

(

JNJ

) is up $0.73 (0.7%) to $102.82 on average volume. Thus far, 3.3 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 8.0 million shares. The stock has ranged in price between $102.00-$102.93 after having opened the day at $102.48 as compared to the previous trading day's close of $102.09.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Johnson & Johnson has a market cap of $286.2 billion and is part of the health care sector. Shares are down 2.4% year-to-date as of the close of trading on Tuesday. Currently there are 8 analysts who rate Johnson & Johnson a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates

Johnson & Johnson

as a

buy

. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Johnson & Johnson Ratings Report

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

null